Destacados día 1
Laura Chu, BSc, MD, MHPE, FRCPC
Staff Neurologist, BARLO MS Centre.
St. Michael ́s Hospital
Assistant Professor, University of Toronto
- Revised McDonald Criteria
- Early initiation of ofatumumab delays disability progression in people with relapsing MS: 6-year results from ALITHIOS Open-Label extension study
- Analysis of health care utilization before the diagnosis of radiologically isolated syndrome does not support the existence of a prodromal phase in MS
Destacados día 2
Carlos Camara Lemarroy, MD
Assistant Professor, Departamento f Clinical Neuroscences
Cumming School of Medicine, university of Calgary
Full Member hotchkiss Brain Institute. Calgary. Alberta
- Ofatumumab as rescue therapy un MS patients previously treated with natalizumab AND Efficacy and safety profile of switching from natalizumab to ofatumumab in highly relapsing-MS: a multicenter real-world study
- Clinically silent MRI lesions are associated with subsequent relapses and disability worsening in treated people with RRMS
Destacados día 3
Alice Schabas,MD,FRCPC
Clinical Assistant Professor.
Division of Neurology University of British Columbia, BC
- Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive MS (MS-STAT2 trial): a multicenter, randomized, placebo-controlled, double-blind phase 3 clinical trial
- Short-term B cell depletion results in medication-free, long-term freedom from disease activity and correction of immune tolerance defect in a subset of people with relapsing MS
Novartis de Colombia S.A. Calle 93B No. 16-31. PBX 654 44 44. Bogotá, D.C. Novartis de Colombia S.A. Novartis Pharma, AG de Basilea, Suiza ® = Marca registrada. Material dirigido a médicos. Más información en el Departamento Médico de Novartis S.A Colombia: 6544444 o al correo [email protected]. Si desea reportar un evento adverso ingrese al siguiente link: https://www.report.novartis.com/es o a través del correo electrónico: [email protected]. Este material no es promocional en lenguaje, apariencia o intención. Si se hace alusión a productos o indicaciones no aprobados por la autoridad regulatoria del país, será bajo el estricto propósito educativo, de genuino intercambio científico y para incluir las alternativas de tratamiento de forma balanceada, completa y vigente. Este material no pretende sustituir o reemplazar una decisión clínica ni terapéutica. No se autoriza la grabación, toma de fotografías y distribución del material y tampoco difusión por medios no autorizados por Novartis. Fecha de aprobación: 09-oct-24, Fecha de Caducidad: 09-oct-26, ID del contenido: FA-11285883.